BioCryst Pharmaceuticals Announces Board and Executive Changes
Ticker: BCRX · Form: 8-K · Filed: Apr 10, 2025 · CIK: 882796
Sentiment: neutral
Topics: executive-change, board-appointment, governance
Related Tickers: BCRX
TL;DR
BioCryst adds two directors and a new CMO, effective April 6, 2025.
AI Summary
BioCryst Pharmaceuticals, Inc. announced on April 6, 2025, changes in its executive team. The company elected two new directors, Dr. Robert J. Radcliff and Ms. Sarah J. Kelly, to its Board of Directors, effective immediately. Additionally, the company appointed Dr. Trevor C. Hall as its new Chief Medical Officer.
Why It Matters
These changes in leadership at BioCryst Pharmaceuticals could signal a strategic shift or a focus on specific areas of growth and development within the company's pipeline.
Risk Assessment
Risk Level: low — This filing reports routine corporate governance changes and executive appointments, which typically carry low inherent risk.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- Dr. Robert J. Radcliff (person) — Newly Elected Director
- Ms. Sarah J. Kelly (person) — Newly Elected Director
- Dr. Trevor C. Hall (person) — Newly Appointed Chief Medical Officer
- April 6, 2025 (date) — Effective date of changes
FAQ
Who were the new directors elected to BioCryst Pharmaceuticals' Board?
Dr. Robert J. Radcliff and Ms. Sarah J. Kelly were elected as new directors.
When were these board and executive changes effective?
The changes were effective as of April 6, 2025.
What is the new role appointed for Dr. Trevor C. Hall?
Dr. Trevor C. Hall was appointed as the new Chief Medical Officer.
What is the principal executive office address for BioCryst Pharmaceuticals?
The principal executive office is located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the IRS Employer Identification Number for BioCryst Pharmaceuticals?
The IRS Employer Identification Number for BioCryst Pharmaceuticals is 62-1413174.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 by Dr. Robert J. Radcliff regarding BIOCRYST PHARMACEUTICALS INC (BCRX).